Bedminster, NJ, United States of America

Thomas Malcolm

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Bedminster, NJ (US) (2019)
  • Andover, NJ (US) (2022)

Company Filing History:


Years Active: 2019-2022

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Thomas Malcolm in Gene Editing

Introduction

Thomas Malcolm is a notable inventor based in Bedminster, NJ (US), recognized for his contributions to the field of gene editing. He holds two patents that focus on innovative methods and compositions aimed at eliminating the risk of JC virus activation and progressive multifocal leukoencephalopathy (PML) during immunosuppressive therapy. His work is significant in advancing therapeutic strategies for patients undergoing such treatments.

Latest Patents

Malcolm's latest patents include groundbreaking methods for gene editing that target the JC virus genome. One of his patents describes a method of eliminating the risk of JC virus activation in subjects undergoing immunosuppressive therapy. This involves administering a gene editing composition that cleaves the target sequence in the JC virus genome, thereby disrupting the virus and eliminating the infection. Additionally, his pharmaceutical compositions include isolated nucleic acid sequences encoding CRISPR-associated endonucleases and various gene editing tools such as TALENs and ZFNs, which are designed to target specific nucleotide sequences in the JC virus genome.

Career Highlights

Throughout his career, Thomas Malcolm has worked with prominent organizations, including Excision Biotherapeutics, Inc. and Temple University. His experience in these institutions has allowed him to collaborate with leading experts in the field, further enhancing his research and innovation capabilities.

Collaborations

Malcolm has collaborated with notable colleagues such as Kamel Khalili and Kenneth I Kohn, contributing to the advancement of gene editing technologies and their applications in medical therapies.

Conclusion

Thomas Malcolm's innovative work in gene editing represents a significant advancement in the fight against viral infections during immunosuppressive therapy. His patents and collaborations highlight his commitment to improving patient outcomes through scientific innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…